Nyxoah募集77M元, 在美国及全球FDA批准后, 扩大Genio睡眠器械。 Nyxoah raises $77M to expand Genio sleep apnea device in U.S. and globally post-FDA approval.

Nyxoah通过私人股权安排、注册的直接出价和可兑换债券协议获得高达7 700万美元的资金,以支持美国将Genio睡眠apnea治疗装置商业化,扩大国际范围,促进临床研究,并为研发提供资金。 Nyxoah has secured up to $77 million in financing through a private equity placement, a registered direct offering, and a convertible bond agreement to support the U.S. commercialization of its Genio sleep apnea treatment device, expand internationally, advance clinical research, and fund R&D. 经费支持后,FDA批准了Genio,该药物刺激下神经治疗阻塞性睡眠呼吸暂停,并与Inspire Medical发生专利纠纷,股东对Inspire提起诉讼,可能创造市场机会. The funding follows FDA approval of Genio, which stimulates the hypoglossal nerve to treat obstructive sleep apnea, and comes amid a patent dispute with Inspire Medical and a shareholder lawsuit against Inspire, potentially creating market opportunities.